CN116710463A - 用于抑制nav1.8电压门控钠通道和治疗nav1.8介导的疾病的化学化合物 - Google Patents
用于抑制nav1.8电压门控钠通道和治疗nav1.8介导的疾病的化学化合物 Download PDFInfo
- Publication number
- CN116710463A CN116710463A CN202180085151.XA CN202180085151A CN116710463A CN 116710463 A CN116710463 A CN 116710463A CN 202180085151 A CN202180085151 A CN 202180085151A CN 116710463 A CN116710463 A CN 116710463A
- Authority
- CN
- China
- Prior art keywords
- pain
- compound
- pharmaceutically acceptable
- acceptable salt
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127341P | 2020-12-18 | 2020-12-18 | |
| US63/127,341 | 2020-12-18 | ||
| PCT/EP2021/086101 WO2022129283A1 (en) | 2020-12-18 | 2021-12-16 | Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116710463A true CN116710463A (zh) | 2023-09-05 |
Family
ID=79025144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180085151.XA Pending CN116710463A (zh) | 2020-12-18 | 2021-12-16 | 用于抑制nav1.8电压门控钠通道和治疗nav1.8介导的疾病的化学化合物 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4262978A1 (https=) |
| JP (1) | JP2024502231A (https=) |
| KR (1) | KR20230121827A (https=) |
| CN (1) | CN116710463A (https=) |
| AU (1) | AU2021403606B2 (https=) |
| CA (1) | CA3202328A1 (https=) |
| CL (1) | CL2023001750A1 (https=) |
| CO (1) | CO2023008049A2 (https=) |
| IL (1) | IL303795A (https=) |
| MX (1) | MX2023007244A (https=) |
| PH (1) | PH12023551406A1 (https=) |
| SA (1) | SA523441263B1 (https=) |
| WO (1) | WO2022129283A1 (https=) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150166589A1 (en) * | 2013-12-13 | 2015-06-18 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201322602D0 (en) * | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| EP3625214B1 (en) * | 2017-05-16 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| MX2021015605A (es) * | 2019-06-27 | 2022-02-16 | Glaxosmithkline Ip Dev Ltd | Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8. |
-
2021
- 2021-12-16 EP EP21831047.2A patent/EP4262978A1/en active Pending
- 2021-12-16 WO PCT/EP2021/086101 patent/WO2022129283A1/en not_active Ceased
- 2021-12-16 JP JP2023536951A patent/JP2024502231A/ja not_active Ceased
- 2021-12-16 KR KR1020237023878A patent/KR20230121827A/ko active Pending
- 2021-12-16 MX MX2023007244A patent/MX2023007244A/es unknown
- 2021-12-16 AU AU2021403606A patent/AU2021403606B2/en active Active
- 2021-12-16 PH PH1/2023/551406A patent/PH12023551406A1/en unknown
- 2021-12-16 IL IL303795A patent/IL303795A/en unknown
- 2021-12-16 CN CN202180085151.XA patent/CN116710463A/zh active Pending
- 2021-12-16 CA CA3202328A patent/CA3202328A1/en active Pending
-
2023
- 2023-06-15 CL CL2023001750A patent/CL2023001750A1/es unknown
- 2023-06-18 SA SA523441263A patent/SA523441263B1/ar unknown
- 2023-06-21 CO CONC2023/0008049A patent/CO2023008049A2/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150166589A1 (en) * | 2013-12-13 | 2015-06-18 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023007244A (es) | 2023-06-29 |
| CL2023001750A1 (es) | 2024-01-19 |
| CO2023008049A2 (es) | 2023-06-30 |
| JP2024502231A (ja) | 2024-01-18 |
| SA523441263B1 (ar) | 2025-01-07 |
| AU2021403606B2 (en) | 2024-11-14 |
| KR20230121827A (ko) | 2023-08-21 |
| PH12023551406A1 (en) | 2024-01-22 |
| IL303795A (en) | 2023-08-01 |
| AU2021403606A1 (en) | 2023-06-22 |
| WO2022129283A1 (en) | 2022-06-23 |
| EP4262978A1 (en) | 2023-10-25 |
| CA3202328A1 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7579805B2 (ja) | アミノ酸化合物の剤形およびレジメン | |
| JP7039802B2 (ja) | Ｒｈｏ－関連プロテインキナーゼ阻害剤、ｒｈｏ－関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用 | |
| JP5795630B2 (ja) | 抗癌及び抗増殖活性を示すシクロプロピルジカルボキサミド及び類似体 | |
| CN115135650A (zh) | 作为kras抑制剂的吡啶并嘧啶衍生物 | |
| JP4493503B2 (ja) | 複素環式化合物及びそれを有効成分とする抗腫瘍剤 | |
| US8518936B2 (en) | Method for preparing acid addition salts of polyacidic basic compounds | |
| WO1995028387A1 (en) | Benzamide compound and medicinal use thereof | |
| CN116601153B (zh) | 作为nav1.8抑制剂的含氮2,3-二氢喹唑啉酮化合物 | |
| KR20210003807A (ko) | Egfr 3중 돌연변이 억제제로서의 퀴나졸린 화합물 및 이의 응용 | |
| CA3253274A1 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH THE ACTIVITY OF THE LPA RECIPIENT | |
| US20250084112A1 (en) | Chemical Compounds Useful for Inhibiting Nav1.8 Voltage-Gated Sodium Channels and Treating Nav1.8 Mediated Diseases | |
| CN116710463A (zh) | 用于抑制nav1.8电压门控钠通道和治疗nav1.8介导的疾病的化学化合物 | |
| CA3212863A1 (en) | Indoline derivatives as ddr1 and ddr2 inhibitors | |
| US20230416287A1 (en) | Chemical Compounds | |
| JPH05112559A (ja) | ４−アミノ−５−ピリミジンカルボン酸誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Country or region after: United Kingdom Address after: Steve Niki Applicant after: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT Ltd. Address before: British Meader Sykes Applicant before: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT Ltd. Country or region before: United Kingdom |